1) Glucocorticoid-induced osteoporosis
糖皮质激素性骨质疏松
1.
The association between glucocorticoid-induced osteoporosis and oral health remains a matter of controversy.
随着糖皮质激素在临床上的广泛应用,糖皮质激素性骨质疏松症发病率明显增加。
2) Glucocorticoid induced osteoporosis
糖皮质激素性骨质疏松
1.
Experimental study on therapeutic effects of amylin on glucocorticoid induced osteoporosis in rats;
胰淀素治疗糖皮质激素性骨质疏松大鼠的实验研究
3) glucocorticoid-induced osteoporosis
糖皮质激素性骨质疏松症
1.
An experimental study on pathogenesis and prevention of glucocorticoid-induced osteoporosis;
糖皮质激素性骨质疏松症的发病机制和预防实验研究
2.
Glucocorticoid-induced osteoporosis is the most frequent secondary osteoporosis, Osteoporotic fractures often result in delayed union and nounion.
糖皮质激素性骨质疏松症是最常见的继发性骨质疏松症,由此引起的病理性骨折常常延迟愈合或不愈合,致残率极高,是骨科领域的一项世界性难题。
4) Corticosteroid-induced osteoporosis
糖皮质激素引起的骨质疏松
5) Osteoporotic
骨质疏松性
1.
Prediction for Risks of Osteoporotic Fracture in Elderly;
老年人骨质疏松性骨折的风险预测
6) Diabetic osteoporosis
糖尿病性骨质疏松症
1.
To study the characteristics of clinical syndromes in diabetic osteoporosis and its early diagnostic and therapeutic methods.
为了解糖尿病性骨质疏松症患者的临床证候特点 ,探讨其早期诊断思路与治法 ,对 42例患者进行临床症状、体征调查及证候辨证 ,结果显示肾虚髓亏、脾气不足、血行不畅在所有患者中均存在 ,为糖尿病性骨质疏松症的主证 ,提示该病的治则应以益肾、健脾、补髓、壮骨、活血相结合 ,临床可以根据其主证及常见症状作出早期诊
2.
To study the clinical effects of QIANGGUBAO(QGB) on diabetic osteoporosis(DOP),the changes of clinical symptoms and bone density in 40 cases before and after being treated with DOP were observed.
为了解强骨宝对糖尿病性骨质疏松症 ( DOP)的临床疗效 ,对 4 0例 DOP患者进行强骨宝颗粒剂用药前后临床症状、骨密度等指标变化的观察。
补充资料：促皮质素释放因子促肾上腺皮质激素释放激素
分子式：
CAS号：
性质：又称促皮质素释放因子，促肾上腺皮质(素)激素释放激素。下丘脑所分泌的激素释放因子之一，系41肽，促进垂体前叶释放ACTH。可作诊断助剂(Cushing Cushing’s综合征，即肾上腺皮质机能亢进症)，抗炎剂。
CAS号：
性质：又称促皮质素释放因子，促肾上腺皮质(素)激素释放激素。下丘脑所分泌的激素释放因子之一，系41肽，促进垂体前叶释放ACTH。可作诊断助剂(Cushing Cushing’s综合征，即肾上腺皮质机能亢进症)，抗炎剂。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条